Full-Time
Product Architect
Ecommerce
Updated on 9/3/2026
Medline
10,001+ employees
Manufacturer and distributor of medical supplies
No salary listed
Pune, Maharashtra, India
In Person
Bachelor's
 IT Operations |
|---|
Get referred to Medline
See people who can refer or advise you
- A bachelor's degree in computer science, information technology, systems engineering, or a related study.
- At least 5 years of experience across multiple information technology solution development disciplines, including technical or infrastructure architecture, network management, application development, middleware, database management, or cloud development.
- Experience delivering presentations to senior-level executives and technical audiences.
- Experience with software development technologies such as JavaScript, HTML, CSS, Java, .NET, PHP, and ABAP.
- Experience with database technologies such as Microsoft SQL Server, MongoDB, Oracle, and HANA.
- Experience developing system designs, strategies, evaluations, and roadmaps.
- Ability to communicate effectively with technical and non-technical staff at all organizational levels.
- Understanding of product management, Agile principles, and development methodologies, including the ability to advise Agile teams on opportunities, impact, risks, and technical or architectural debt.
- Strong interpersonal, leadership, analytical, technical, planning, and organizational skills.
- Ability to influence, guide, and facilitate stakeholders and peers in decision-making.
- Knowledge of business, information, data, network, and security aspects of enterprise technology architecture.
- Ability to understand and apply diagramming and modeling techniques.
- Understanding of strategic and emerging technology trends and their practical application to evolving business and operating models.
- Ability to work effectively in a team environment and lead cross-functional teams.
- Strong understanding of the company's processes, organization, customers, and business models.
- Lead evaluation, design, and analysis for implementing solutions architecture across an assigned portfolio and groups of business applications or technologies.
- Collaborate with management, business leaders, portfolio stakeholders, and enterprise architecture to connect business roadmaps with operational decisions.
- Identify the organizational impact, including effects on skills, processes, structures, and culture, and the financial impact of solutions architecture.
- Translate business and technical requirements into architectural blueprints that achieve business objectives and document architecture design and analysis work.
- Work with product owners and project or product managers to maintain an architectural runway that supports future business requirements throughout the product lifecycle.
- Lead troubleshooting and operational support initiatives within the portfolio, including technical upgrades, system patches, and outage support.
- Experience working with multi-site global teams.
- At least 4 years of DevSecOps experience, including unit testing, continuous integration and continuous delivery, security compliance, and functional, performance, and stress-test automation.
- Experience architecting secure healthcare applications and familiarity with protected health information, personally identifiable information, and Health Insurance Portability and Accountability Act compliance requirements.
- Ability to apply multiple technical solutions to enable future-state business capabilities and drive targeted business outcomes.
- Ability to balance long-term and short-term implications of individual decisions.
- Ability to remain unbiased toward specific technology or vendor choices and prioritize results over personal preferences.
- Understanding and knowledge of an Agile system development life cycle methodology such as Scrum at Scale, Scaled Agile Framework, or Kanban.
- Ability to influence and persuade business and information technology leaders and development teams.
- Ability to estimate the financial impact of technology alternatives.
- Ability to quickly comprehend existing, new, and emerging technologies that enable new business designs and models.
Medline Industries designs, produces, and distributes medical supplies for healthcare settings. It combines manufacturing and distribution to control product quality and sell directly to hospitals and other healthcare providers, offering a wide range of Medline-branded and third-party products. Its products include gowns, uniforms, gloves, and other medical consumables, produced and then delivered through a direct-to-provider model. The company differentiates itself with vertical integration that bypasses traditional distributors, a long-standing family-led culture that continued after a 2021 private-equity-led majority investment, and the scale to serve healthcare systems with a broad catalog. The goal is to supply healthcare providers with a comprehensive, high-quality catalog of medical products while expanding market reach and maintaining reliability through direct manufacturing-and-distribution control.
Company Size
10,001+
Company Stage
IPO
Headquarters
Northfield, Illinois
Founded
1966
Get referred to Medline
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales rose 11.6% to $7.7 billion, driven by new customer signings.
- Medline booked $243 million tariff refunds after the Supreme Court's February 2026 IEEPA ruling.
- California rebuilds add 1.6 million square feet in Tracy and Stockton, with Perris underway.
What critics are saying
- FDA warning letters in April and June 2026 expose systemic quality failures.
- July 2026 neonatal breathing-circuit recall and lawsuit investigations deepen brand and liability damage.
- Another major manufacturing lapse could trigger supply interruptions, contract losses, and regulatory shutdowns.
What makes Medline unique
- Medline combines manufacturing and distribution, controlling quality, pricing, and delivery speed.
- Its 45,000-person global network serves 100 countries and 12 Allina hospitals plus 90 clinics.
- Private-equity backing from Blackstone, Carlyle, and H&F funds large-scale logistics and automation.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Life Insurance
Disability Insurance
401(k) Company Match
Paid Vacation
Paid Sick Leave
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 0%2 year growth
↑ 0%Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference. September 03, 2026 08:30 ET | Source: Medline Inc. NORTHFIELD, Ill., Sept. 03, 2026 (GLOBE NEWSWIRE) - Medline Inc. ("Medline") (Nasdaq: MDLN) today announced that Jim Boyle, chief executive officer, and Mike Drazin, chief financial officer, are scheduled to present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY, on Tuesday, September 15, 2026, at 12:20pm ET. A webcast of the presentation will be available on the Events page of Medline's Investor Relations website at ir.medline.com. A replay of the webcast will be available on Medline's Investor Relations website for 90 days following the event. About Medline Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Illinois, the company employs more than 45,000 people worldwide and operates in more than 100 countries. To learn more about how Medline makes healthcare run better, visit www.medline.com. Contacts Investor Relations: Karen King Global Head of Investor Relations Patrick Flaherty Director, Investor Relations Media Relations: Ben Fox Vice President, Corporate Communications (224) 327-9999 [email protected] Recommended reading.
Medline tallies tariff refunds as Q2 sales rise 11.6%. Brian Warmoth | Aug 18, 2026 2.5 minutes Medical supplies distributor Medline recorded $243 million in tariff refunds during its fiscal year through Q2, helping drive revenue growth even as a California warehouse fire weighed on quarterly profits. Medline Inc. recorded $243 million in net tariff refunds that it realized during its current fiscal year by the end of its Q2. Those funds arrived against the backdrop of an overall net income decline of 58.3% year over year to $139 million for the quarter ended June 27. Despite that decrease, the medical supply company outlined its growth plans for the rest of its fiscal year. In addition, it reported an overall sales increase of 11.6% to $7.7 billion for the same period. Jim Boyle, chief executive officer of Medline, said Q2 reflected "strong execution of our growth strategy" and "operational resilience." What drove Medline sales in Q2? Medline credited existing customer growth and new customer signings from 2025 for its rise in Q2 sales. It noted in an earnings release that the latest total accounted for $89 million of accrued customer repayments. Those were associated with refunds from International Emergency Economic Powers Act (IEEPA) tariffs. Those refunds were processed following the U.S. Supreme Court's ruling in February 2026, which found that IEEPA tariffs were not appropriately authorized. Meanwhile, Medline attributed its drop in income to complications related to a June fire. That disaster damaged one of its distribution centers in California. "We delivered robust top-line growth in the quarter, secured over 65% of our annual goal in total new customer signings during the first half of 2026, and moved swiftly to minimize disruption from the fire at our Tracy, California, distribution center, demonstrating an unwavering commitment to our customers," Boyle said. "At the same time, we are effectively managing a dynamic external environment while investing in strategic initiatives to strengthen our market position and support long-term shareholder value creation." Impact from the Tracy fire on Medline. During Medline's Q2 earnings call, Michael Drazin, the company's chief financial officer, assessed that the "Tracy fire impact is transitory and will have some impact rolling in '27." Looking ahead, he told analysts that he expected to see improvements to the situation. Medline is setting up new California distribution centers based in Tracy and Stockton, adding new automation at those facilities. "Obviously, the operational investments and some of the quality investments will be more permanent in nature and will roll into our base in 2027," Drazin said. At the same time, Medline lowered its guidance for adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) in its full-year 2026 outlook. That outlook fell to a range of $3.3 billion to $3.4 billion from $3.5 billion to $3.6 billion previously. "Our outlook reflects several headwinds, including the Middle East conflict, the Tracy warehouse fire, growth-related operational investments, quality remediation efforts and softness in our retail business," Boyle stated.
MDLN investigation: Kessler Topaz Meltzer & Check, LLP encourages Medline Inc. (NASDAQ: MDLN) investors to contact the firm. Aug 13, 2026, 18:40 ET RADNOR, Pa., Aug. 13, 2026 /PRNewswire/ - Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Medline Inc. (NASDAQ: MDLN) on behalf of investors who purchased or acquired Medline Inc. Class A common stock and experienced significant financial losses. Medline Reveals Significant FDA Violations On June 2, 2026, the FDA published a warning letter dated May 28, 2026 addressed to Medline summarizing "significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals[.]" Specifically, the FDA letter stated that Medline "failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications." According to a June 3, 2026 Reuters article, the latest FDA warning letter to Medline relates to "violations of manufacturing quality standards" and is "the second such action against the (C) ompany in two months." Further, the Reuters article states that according to the FDA, Medline "failed to thoroughly investigate microbial contamination incidents in finished drug products and also cited inadequate cleaning practices." Why Did Medline's Stock Drop? Following the news of Medline's FDA violations, the company's stock price fell over 7%. Then, on August 5, 2026, Medline's stock price dropped by over 12% in response to the company's second quarter results and lowered full-year adjusted EBITDA guidance. Investors who purchased Medline Inc. (NASDAQ: MDLN) Class A common stock and experienced losses may have legal rights under the federal securities laws. CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS: If you purchased or acquired Medline Inc. Class A common stock and have lost money on your investment, please provide your information here: https://www.ktmc.com/mdln-medline-inc-investigation?utm_campaign=hc?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=mdln&mktm=PR You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. There is no cost or obligation to speak with an attorney. ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC): Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500's Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. SOURCE Kessler Topaz Meltzer & Check, LLP
News for rocket scientists. NASDAQ: MDLN investigation reminder: Kessler Topaz Meltzer & Check, LLP encourages Medline Inc. (NASDAQ: MDLN) investors to contact the firm. RADNOR, Pa., Aug. 7, 2026 /PRNewswire/ - Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Medline Inc. (NASDAQ: MDLN) on behalf of investors who purchased or acquired Medline Inc. Class A common stock and experienced significant financial losses. Medline Reveals Significant FDA Violations On June 2, 2026, the FDA published a warning letter dated May 28, 2026 addressed to Medline summarizing "significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals[.]" Specifically, the FDA letter stated that Medline "failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications." According to a June 3, 2026 Reuters article, the latest FDA warning letter to Medline relates to "violations of manufacturing quality standards" and is "the second such action against the (C) ompany in two months." Further, the Reuters article states that according to the FDA, Medline "failed to thoroughly investigate microbial contamination incidents in finished drug products and also cited inadequate cleaning practices." Why Did Medline's Stock Drop? Following the news of Medline's FDA violations, the company's stock price fell over 7%. Then, on August 5, 2026, Medline's stock price dropped by over 12% in response to the company's second quarter results and lowered full-year adjusted EBITDA guidance. Investors who purchased Medline Inc. (NASDAQ: MDLN) Class A common stock and experienced losses may have legal rights under the federal securities laws. CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS: If you purchased or acquired Medline Inc. Class A common stock and have lost money on your investment, please provide your information here: https://www.ktmc.com/mdln-medline-inc-investigation?utm_campaign=hc?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=mdln&mktm=PR You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. There is no cost or obligation to speak with an attorney. ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC): Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500's Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for its clients and the classes they represent. May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. SOURCE Kessler Topaz Meltzer & Check, LLP
Medline Industries, LP issues nationwide recall of Hudson RCI Neonatal/Infant Heated Wire Breathing Circuits. When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company. Summary. * Company Announcement Date: - August 05, 2026 * FDA Publish Date: - August 06, 2026 * Product Type: - Medical Devices * Reason for Announcement: - Due to heated wire connector (pigtail) at the Neptune humidifier may exhibit discoloration, melting, smoke, burning odor, or other signs of localized thermal damage * Company Name: - Medline Industries, LP * Brand Name: - Medline, Teleflex * Product Description: - Hudson RCI Neonatal/Infant Heated Wire Breathing Circuits Company Announcement. On July 13, 2026, Medline Industries, LP initiated a nationwide recall of Hudson RCI Neonatal/Infant Heated Wire Breathing Circuits. Medline received reports of sporadic failures involving the electrical connector of certain neonatal and infant heated wire breathing circuits. In affected circuits, the heated wire connector (pigtail) at the Neptune humidifier may exhibit discoloration, melting, smoke, burning odor, or other signs of localized thermal damage. To date, reported events have occurred infrequently relative to the number of devices distributed, with the observed occurrence rate of 0.011% across the distributed population. Refer to the below photographs of the product and a defect that was reported to Medline. The Neptune humidifier is designed with safety features that continually monitor the heated wire circuit and automatically discontinues power to the heated wires when electrical abnormalities are detected. When power to the heated wires is disconnected, respiratory gas flow to the patient continues. The disconnection of power is limited to the heated wire function. Continued delivery of inadequately heated or unconditioned gas can desiccate and damage the airway epithelium, predisposing the infant to bronchospasm, inspissated secretions, and airway obstruction. Potential continued loss of heated wire function may result in increased circuit condensation (rainout), which can cause inadvertent positive end-expiratory pressure (PEEP), circuit obstruction, or accidental lavage of pooled fluid into the infant's airway, reduced humidity and delivery of cold, dry gas increases the risk of cold stress, leading to elevated oxygen consumption and worsening respiratory distress. Consumers who have the affected Hudson RCI Neonatal/Infant Heated Wire Breathing Circuits should stop using and discard the device. Consumers should not return product to Medline. Medline voluntarily recalled product after thorough investigation of reports received for this issue and notified the FDA of this action. At this time, Medline is not aware of any serious health consequences which have occurred due to use of the device. Recalled Hudson RCI Neonatal/Infant Heated Wire Breathing Circuits were manufactured on or before July 8, 2026 and distributed from June 28, 2021, to July 31, 2026. Hudson RCI Neonatal/Infant Heated Wire Breathing Circuits within the scope of the recall can be identified by their product labeling, which includes the name of the device, item number, and manufacturing date. The labeling of products affected by the recall include either a Teleflex or Medline item number, depending on the manufacturing date. Affected products manufactured before January 2024 display a Teleflex label and item number, while products manufactured starting January 2024 or later display a Medline label and item number. Please refer to the example labels below to identify the manufacturing date (red) and item number (blue) on the product label. The following item numbers are included in the scope of the recall: | Medline Item Number | Teleflex Item Number | | HUD78001KIT | 780-01KIT | | HUD78007 | 780-07 | | HUD78007KIT | 780-07KIT | | HUD78008KIT | 780-08KIT | | HUD78009 | 780-09 | | HUD78009KIT | 780-09KIT | | HUD78013 | 780-13 | | HUD78014 | 780-14 | | HUD78015 | 780-15 | | HUD78017KIT | 780-17KIT | | HUD78018 | 780-18 | | HUD78018KIT | 780-18KIT | | HUD78019 | 780-19 | | HUD88001KIT | 880-01KIT | | HUD88013KIT | 880-13KIT | | HUD88014KIT | 880-14KIT | | HUD88015KIT | 880-15KIT | | HUD88017KIT | 880-17KIT | All product manufactured on or after July 9, 2026 are not under scope of the recall and may continue to be used. Medline is notifying its distributors and customers by email and/or first-class mail and is arranging for credit of all recalled product(s). Consumers with questions regarding this recall can contact Medline by phone at 866-359-1704 Monday through Friday between the hours of 8am and 5pm CST or [email protected]. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this medical device. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. * Complete and submit the report Online: www.fda.gov/medwatch/report.htm * Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-3321088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 Company contact information.